Related Experiment Video
Updated: May 26, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Novel therapies in phase II and III trials for malignant pleural mesothelioma
Marjorie G Zauderer1, Lee M Krug
1Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA.
Abstract:
Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the desperate need to develop better treatment for this disease, the rarity of the tumor type creates formidable challenges in clinical research. Nonetheless, several novel agents are under investigation. Most efforts are directed toward improving standard first-line therapy with pemetrexed and cisplatin, or developing effective second-line treatments. Several classes of drugs are being explored, including those that impact DNA transcription, cell-cycle progression, angiogenesis, and immune tolerance. This article describes several ongoing or recently completed phase II and III trials using novel agents vorinostat, everolimus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine, bevacizumab, cediranib, and thalidomide.
Insights
Mesothelioma, a rare pleural cancer, has few treatments. Researchers are investigating novel agents and improving current therapies like pemetrexed and cisplatin to find better options for this challenging disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Mesothelioma is a rare pleural malignancy with limited therapeutic options.
- The rarity of mesothelioma presents significant challenges for clinical research and treatment development.
Purpose of the Study:
- To review novel therapeutic agents and ongoing clinical trials for mesothelioma.
- To explore strategies for improving both first-line and second-line treatments for this rare cancer.
Main Methods:
- Review of ongoing and recently completed Phase II and III clinical trials.
- Investigation of novel agents targeting DNA transcription, cell-cycle progression, angiogenesis, and immune tolerance.
Main Results:
- Several novel agents including vorinostat, everolimus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine, bevacizumab, cediranib, and thalidomide are under investigation.
- Efforts are focused on enhancing standard first-line therapy (pemetrexed and cisplatin) and developing effective second-line treatments.
Conclusions:
- Novel agents targeting diverse pathways show promise for mesothelioma treatment.
- Continued clinical research is crucial to overcome the challenges posed by mesothelioma's rarity and limited therapeutic options.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...